OncLive TV

Renee Saliby, MD, MSc discusses the relationship between intermediate end points and overall survival in metastatic renal cell carcinoma.

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

Alastair Thompson, BSc, MBChB, MD, FRCS, discusses ongoing trials evaluating de-escalated treatment in early-stage breast cancer.

C. Ola Landgren, MD, PhD, discusses standard treatment approaches and the advantages of quadruplet regimens in newly diagnosed multiple myeloma.

Sara M. Tolaney, MD, MPH, discusses the ongoing development of mutation-selective PI3K inhibitors in PI3K-mutant metastatic breast cancer.

Adam M. Brufsky, MD, PhD, FACP, discusses the unique design of the allogeneic GM-CSF–secreting breast cancer vaccine SV-BR-1-GM.

Justin M. Watts, MD, discusses the design and purpose of a phase 1 trial evaluating INCB057643 in myelofibrosis and other advanced myeloid neoplasms.

Sara M. Tolaney, MD, MPH, discusses the potential role for biomarkers in guiding treatment decisions in early-stage HER2-positive breast cancer.

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of surgical resectability in patients with borderline resectable NSCLC.

Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC.

Chirag Shah, MD, discusses ongoing clinical trials aiming to minimize surgical intervention in locoregional breast cancer.

Jason A. Mouabbi, MD, discusses clinical trials aimed at expanding the treatment paradigm for invasive lobular breast cancer.

Roger Li, MD, discusses persisting unmet needs in high-risk, muscle-invasive bladder cancer.

Joseph Franses, MD, PhD, discusses the need for more prospective data in the second-line setting and beyond for patients with hepatocellular carcinoma.

Brian I. Rini, MD, FASCO, discusses an analysis of clustering from the KEYNOTE-426 study in patients with advanced renal cell carcinoma.

Marc-Oliver Grimm, MD, discusses a post-hoc analysis of the ARASENS trial in metastatic hormone-sensitive prostate cancer.

David Samuel Dicapua Siegel, MD, discusses unmet needs and current challenges within multiple myeloma.

Moritz Fürstenau, MD, discusses the rationale for launching the phase 3 GAIA/CLL13 in previously untreated, fit patients with chronic lymphocytic leukemia.

Shipra Gandhi, MD, discusses considerations for continuing with a CDK4/6 inhibitor or switching therapies in HER2- negative advanced breast cancer.

Chih-Yi Liao, MD, discusses key considerations for the selection of single-agent vs combination regimens in frontline metastatic hepatocellular carcinoma.

Mazyar Shadman, MD, MPH, discusses the rationale for combining sonrotoclax plus zanubrutinib for treatment-naive chronic lymphocytic leukemia.

Sheldon Feldman, MD discusses new approaches for decreasing the risk of and managing breast cancer¬–related lymphedema.

Rita Mukhtar, MD, discusses challenges in the diagnosis and management of invasive lobular carcinoma.

Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.

Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.

Joseph Franses, MD, PhD, discusses treatment considerations for hepatocellular carcinoma that progresses after first-line therapy.

Marc Machaalani, MD, discusses how inhibition of AXL and c-Met may prevent acquired resistance to c-Met inhibitors in renal cell carcinoma.

Craig Eckfeldt, MD, PhD, discusses how improved minimal residual disease testing methods have impacted the acute myeloid leukemia treatment paradigm.

Alicia Morgans, MD, MPH, discusses data from the ARAMIS trial showing the association between PSA levels and radiological progression in nmCRPC.